Hims & Hers: Profitable Growth or Just Another Overhyped IPO?
Okay, so Hims & Hers (HIMS). Another one of these "disruptive" companies that IPO'd and promised to change the world. But are they actually doing anything, or is it just marketing hype and GLP-1 injections?
The Numbers Game: Are They Real?
Let's look at the numbers. Q3 2025, revenue up 49% year-over-year, net income of $16 million. Subscribers grew 21%. Sounds great, right? Except... gross margin down from 79% to 74%. Net income way down compared to last year, which included a tax benefit. They spin it as "strong, profitable growth," but is it really?
And what about this quote from CEO Andrew Dudum: "We’re building a platform that gets more personal, more proactive..." Translation: "We're trying to collect as much data on you as possible so we can sell you more stuff." I mean, come on, let's be real. This is a business, not a charity.
They're talking to Novo Nordisk about distributing Wegovy. Smart move, offcourse, ride the weight loss wave. But GLP-1s are a crowded market, and Novo Nordisk already has a head start. What happens when the hype dies down? Will Hims & Hers be left holding the bag? And what about the competition from companies like Palantir (PLTR stock) , or even the big boys like UNH stock.
The Roller Coaster Ride: Can You Stomach the Volatility?
The article mentions the stock has been a "roller coaster ride." HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? Gains of 173%, then a 63% drop. Another 146% gain, followed by a 36% plunge. Up 60%, then down 45%. Seriously? Who wants to invest in that kind of chaos? It's like trying to catch a falling knife.
They say the fundamentals are strong, debt management is exemplary. But then they admit the short interest is a whopping 37.54% of the float. That's a HUGE red flag. Are that many people betting against the stock for no reason? I doubt it. And what about the "analysts" with their price targets? They're always wrong anyway.
Oh, and get this - the company offers compounded GLP-1 injections. So they're not even selling the real deal, just knock-offs? That doesn't exactly inspire confidence. I'm not saying it's illegal, but it feels… shady.
Another thing that bothers me is the whole "telehealth" angle. Sure, it's convenient, but is it really better healthcare? Are people getting the personalized attention they need, or are they just getting a quick prescription from some overworked doctor who's more interested in hitting their quota? I'm not convinced.
And let's not forget the marketing. All those ads targeted at young men with ED or hair loss. It feels predatory, preying on insecurities to make a buck. Is that really the kind of company we want to support?
Then again, maybe I'm just being too cynical. Maybe Hims & Hers really is trying to make a difference. But I ain't buying it. Not yet, anyway.
So, Is This Just Another Pump and Dump?
Look, the numbers are okay, but the volatility is insane. The business model feels a little… opportunistic. The marketing is borderline unethical. I'm not saying Hims & Hers is a scam, but I'm not rushing out to buy the stock either. There are plenty of other fish in the sea, and I'd rather invest in something that doesn't feel like such a gamble. nvda stock looks far more promising.
